 So the candle trial is a very important phase three trial which we will see here for the first time at the late-breaking session at us. And this compared in a randomized manner treatment combination with direct tumour map as the NTCD38 antibody in combination with calfilsumab as the proteasome inhibitor and exomethazone versus calfilsumab and exomethazone alone and more than 450 patients contributed to this trial which was conducted all over the world and they were two-to-one randomized for direct tumour map KD or KD alone and the trial now shows that the combination of direct tumour map with calfilsumab and exomethazone is highly superior to calfilsumab and exomethazone alone and the primary endpoint of the trial was the progression-free survival. This was not reached for the direct tumour map calfilsumab arm and was like close to 16 months for the conventional calfilsumab and exomethazone so in the expected manner and so that we can say that the trials had a new standard of care with this triplet of direct tumour map calfilsumab and exomethazone. This trial has a huge implication for all of our patients in Europe. There is a clear trend towards using linalidomide in first-line treatment independent of patients undergo a transplant where patients receive standard for example linalidomide maintenance after transplant also for patients not undergoing a transplant where linalidomide exomethazone VRD and also now just recently direct tumour map lendex is approved and so we generate more and more patients who are then refractory to linalidomide when they go to second-line treatment or third-line treatment and for those patients the direct tumour map calfilsumab and exomethazone combination is then a major and very important treatment option so I think this will very rapidly translate in a standard of care. The quality of life assessment will be published separately what we currently know is that the quality of life was kept although the patients in the DERA arm had a triplet. The calfilsumab regimen is always a bit of a challenge with the twice weekly application and in Europe in contrast to the US we have no approval currently for the once weekly application however there's a huge interest to make it easier for patients so we are working all together to also establish regimens where the direct tumour calfilsumab combination can be given once weekly for calfilsumab. Currently we have the choice in relapse we have many approved drugs and many approved drug combinations however we generate patients in different situations patients receive different regimens in first line so we look what patients had how long they responded how they tolerated it we have to look on patients age we have to consider the distance to the next center we have to consider the different availabilities of regimens all across Europe with the approval of the competent authority in Europe it doesn't mean necessarily that the negotiations are all made in the different countries we have to consider potential toxicities we have to consider the comorbidities of our patients so it's a patient individual decision and the opinion of the patient is of high relevance what is the goal the patient wants to achieve with this disease what is surrounding what does the family think and what's his role in the world so we have to discuss that together and those different opportunities give us the opportunity to make a good decision for each individual patient hopefully for the direct tumour map KD I'm very confident that we have a rapid approval and then it depends again on the negotiation procedures in the individual countries but we will do as the treating physicians in those trials we will do our very best to support the rapid access because I think this is a real important treatment combination which should be offered soon to everyone